Advertisement

Journal of Molecular Medicine

, Volume 83, Issue 8, pp 647–654 | Cite as

Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the α-galactosidase A gene in the Czech and Slovak population

  • Robert Dobrovolny
  • Lenka Dvorakova
  • Jana Ledvinova
  • Sudheera Magage
  • Jan Bultas
  • Jean C. Lubanda
  • Milan Elleder
  • Debora Karetova
  • Marketa Pavlikova
  • Martin Hrebicek
Original Article

Abstract

We have identified 21 different α-galactosidase A gene (GLA) mutations in 22 unrelated Czech and Slovak families with Fabry disease. Eleven of these mutations were novel (point mutations D93N, A135V, D155H, G171R, Q280K, G360S, Q330X, splicing errors c.194ins14, c.801ins36 and deletions c.674_732del59, g.3405_6021del2617). Genotyping of family members for family-specific mutations revealed 55 heterozygotes that manifested clinical symptoms of different severity. To examine the contribution of X-inactivation skewing to disease manifestation in Fabry heterozygotes, we have adopted the Mainz severity scoring scheme and compared the score values with the X-inactivation status in 39 carriers in an age-dependent manner. The age-score trendline of Fabry females who had a predominantly inactivated X-chromosome bearing a wild-type GLA allele (10 of 38 females) was markedly steeper than in the rest of the cohort. One female carrier with an inactivated mutated allele had a low score value when compared to the other heterozygotes of the same age. These data suggest that X-inactivation is indeed a major factor determining the severity of clinical involvement in Fabry heterozygotes. There was a statistically significant difference between the severity score values of heterozygotes with random and non-random X-chromosome inactivation at the 5% level of significance. Further studies will show if the degree of the wildtype allele inactivation will be useful as a predictive marker of severity of phenotype in Fabry heterozygotes. Although the correlation between X-inactivation skewing and presentation of the disease in Fabry heterozygotes has previously been suggested in the literature, this report is among the first attempts to examine this relationship systematically.

Keywords

Fabry disease X-inactivation Mutation Score 

Notes

Acknowledgements

This work was supported by project grants IGA MZ CR NE 5770-3-99, VZ 111100003 and MSM 21620806. We thank Dr. Garman (Structural Biology Section, Laboratory of Immunogenetic Disease, National Institute of Allergy and Infectious Diseases, National Institute of Health) for giving us the coordinates of the human α-gal A structural model. We also thank Dr. Merta and Dr. Reiterová (First Department of Internal Medicine, General Teaching Hospital, Prague) for providing us with biological material from some of the Fabry families.

References

  1. 1.
    Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L (1967) Enzymatic defect in Fabry’s disease. Ceramidetrihexosidase deficiency. N Engl J Med 276:1163–1167PubMedGoogle Scholar
  2. 2.
    Desnick RJ, Ioannou YA, Eng CM (2001) Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 3733–3774Google Scholar
  3. 3.
    MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38:750–760Google Scholar
  4. 4.
    Elleder M, Bradova V, Smid F, Budesinsky M, Harzer K, Kustermann-Kuhn B, Ledvinova J, Belohlavek, Kral V, Dorazilova V (1990) Cardiocyte storage and hypertrophy as a sole manifestation of Fabry’s disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch A Pathol Anat Histopathol 417:449–455Google Scholar
  5. 5.
    Ogawa K, Sugamata K, Funamoto N, Abe T, Sato T, Nagashima K, Ohkawa S (1990) Restricted accumulation of globotriaosylceramide in the hearts of atypical cases of Fabry’s disease. Human Pathol 21:1067–1073Google Scholar
  6. 6.
    Nagao Y, Nakashima H, Fukuhara Y, Shimmoto M, Oshima A, Ikari Y, Mori Y, Sakuraba H, Suzuki Y (1991) Hypertrophic cardiomyopathy in late-onset variant of Fabry disease with high residual activity of alpha-galactosidase A. Clin Genet 39:233–237PubMedGoogle Scholar
  7. 7.
    Ishii S, Sakuraba H, Suzuki Y (1992) Point mutations in the upstream region of the alpha-galactosidase A gene exon 6 in an atypical variant of Fabry disease. Hum Genet 89:29–32PubMedGoogle Scholar
  8. 8.
    Sakuraba H, Oshima A, Fukuhara Y, Shimmoto M, Nagao Y, Bishop DF, Desnick RJ, Suzuki Y (1990) Identification of point mutations in the alpha-galactosidase A gene in classical and atypical hemizygotes with Fabry disease. Am J Hum Genet 47:784–789PubMedGoogle Scholar
  9. 9.
    Scheidt W von, Eng CM, Fitzmaurice TF, Erdmann E, Hubner G, Olsen EG, Christomanou H, Kandolf R, Bishop DF, Desnick RJ (1991) An atypical variant of Fabry’s disease with manifestations confined to the myocardium. N Engl J Med 324:395–399Google Scholar
  10. 10.
    Krawczak M, Cooper DN (1997) The human gene mutation database. Trends Genet 13:121–122Google Scholar
  11. 11.
    Lyon MF (1995) The history of X-chromosome inactivation and relation of recent findings to understanding of human X-linked conditions. Turk J Pediatr 37:125–140Google Scholar
  12. 12.
    Whybra C, Kampmann C, Krummenauer F, Ries M, Mengel E, Miebach E, Baehner F, Kim K, Bajbouj M, Schwarting A et al (2004) The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 65:299–307Google Scholar
  13. 13.
    Mayes JS, Scheerer JB, Sifers RN, Donaldson ML (1981) Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry’s disease. Clin Chim Acta 112:247–251Google Scholar
  14. 14.
    Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156–159CrossRefPubMedGoogle Scholar
  15. 15.
    Davies JP, Winchester BG, Malcolm S (1993) Mutation analysis in patients with the typical form of Anderson-Fabry disease. Hum Mol Genet 2:1051–1053Google Scholar
  16. 16.
    Little S (1998) Amplification-refractory mutation system (ARMS)–analysis of point mutations. In: Dracopoli NC, Haines JL, Korf BR, Moir DT, Morton CC, Seidman CE, Seidman JG, Smith DR (eds) Current protocols in human genetics. Wiley, New York, p 9.8Google Scholar
  17. 17.
    Thompson JD, Higgins DG, Gibson TJ (1994) Clustal W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22:4673–4680PubMedGoogle Scholar
  18. 18.
    Garman SC, Garboczi DN (2004) The molecular defect leading to Fabry disease: structure of human alpha-galactosidase. J Mol Biol 337:319–335Google Scholar
  19. 19.
    Guex N, Peitsch MC (1997) SWISS-MODEL and the Swiss-Pdb viewer: an environment for comparative protein modeling. Electrophoresis 18:2714–2723PubMedGoogle Scholar
  20. 20.
    Allen RC, Zoghbi HY, Moseley AB, Rosenblatt HM, Belmont JW (1992) Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. Am J Hum Genet 51:1229–1239PubMedGoogle Scholar
  21. 21.
    Racchi O, Mangerini R, Rapezzi D, Rolfo M, Gaetani GF, Ferraris AM (1998) X chromosome inactivation patterns in normal females. Blood Cells Mol Diseases 24:439–447Google Scholar
  22. 22.
    Lattuada D, Vigano P, Somigliana E, Odorizzi MP, Vignali M, Di Blasio AM (2004) Androgen receptor gene cytosine, adenine, and guanine trinucleotide repeats in patients with endometriosis. J Soc Gynecol Investig 11:237–240Google Scholar
  23. 23.
    Cotton RG, Horaitis O (2000) Quality control in the discovery, reporting, and recording of genomic variation. Human Mutat 15:16–21Google Scholar
  24. 24.
    Garman S, Garboczi D (2002) Structural basis of Fabry disease. Mol Genet Metab 77:3–11Google Scholar
  25. 25.
    Froissart R, Guffon N, Vanier MT, Desnick RJ, Maire I (2003) Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma. Mol Genet Metab 80:307–314Google Scholar
  26. 26.
    Dobrovolný R, Dvořáková L, Ledvinová J, Magage S, Bultas J, Lubanda JC, Poupětová H, Elleder M, Karetová D, Hřebíček M (2005) Recurrence of Fabry disease as a result of paternal germline mosaicism for alpha-galactosidase A gene mutation. Am J Med Genet (in press)Google Scholar
  27. 27.
    Strachan T, Read AP (1999) Human molecular genetics, vol 2. Wiley-Liss, New YorkGoogle Scholar
  28. 28.
    Barker D, Schafer M, White R (1984) Restriction sites containing CpG show a higher frequency of polymorphism in human DNA. Cell 36:131–138Google Scholar
  29. 29.
    Antonarakis SE, Krawczak M, Cooper DN (2001) The nature and mechanism of human mutation. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited diseases, 8th edn. McGraw-Hill, New York, pp 358–360Google Scholar
  30. 30.
    Redonnet-Vernhet I, Ploos van Amstel JK, Jansen RP, Wevers RA, Salvayre R, Levade T (1996) Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene. J Med Genet 33:682–688Google Scholar
  31. 31.
    Morrone A, Cavicchi C, Bardelli T, Antuzzi D, Rigante D, Parini R, Di Rocco M, Feriozzi S, Gabrielli O, Barone L et al (2002) Mutation analysis and X-inactivation studies in the alpha-galactosidase A gene. Am J Hum Genet 71:421Google Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Robert Dobrovolny
    • 1
  • Lenka Dvorakova
    • 1
  • Jana Ledvinova
    • 1
  • Sudheera Magage
    • 2
  • Jan Bultas
    • 2
  • Jean C. Lubanda
    • 2
  • Milan Elleder
    • 1
  • Debora Karetova
    • 2
  • Marketa Pavlikova
    • 3
  • Martin Hrebicek
    • 1
  1. 1.Institute of Inherited Metabolic Diseases, First Faculty of MedicineCharles UniversityPrague 2Czech Republic
  2. 2.Second Department of Internal MedicineGeneral Teaching HospitalPragueCzech Republic
  3. 3.EuroMISE Center, Institute of Computer ScienceAcademy of Sciences of the Czech RepublicPragueCzech Republic

Personalised recommendations